SOPHiA GENETICS director receives RSU and option grants

SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation.

Rhea-AI Filing Summary

SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation. He was granted 19,724 Ordinary Shares in the form of restricted stock units valued at $5.46 per share, bringing his direct share holdings to 240,220 Ordinary Shares.

He also received options to buy 28,818 Ordinary Shares at an exercise price of $5.46 per share, with 218,569 options held after the grant. Both the RSUs and the options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service.

Insider Trade Summary

Grant/Award: 48,542 shares

Grant/Award 2 txns

Insider HIRSCH DIDIER

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	28,818	$5.46	$157K
Grant/Award	Ordinary Shares	19,724	$5.46	$108K

Holdings After Transaction: Share Option (Right to Buy) — 218,569 contracts (Direct); Ordinary Shares — 240,220 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.
2. F2. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Key Figures

RSU grant: 19,724 shares at $5.46 Options granted: 28,818 options at $5.46 Shares held after grant: 240,220 Ordinary Shares +2 more

5 metrics

RSU grant 19,724 shares at $5.46 Restricted stock units granted on June 18, 2026

Options granted 28,818 options at $5.46 Share options granted on June 18, 2026

Shares held after grant 240,220 Ordinary Shares Direct holdings after RSU grant

Options held after grant 218,569 options Total options following reported transaction

Option expiration June 18, 2036 Expiration date of granted share options

Key Terms

restricted stock unit ("RSU"), Share Option (Right to Buy), vest 100%, annual meeting of shareholders

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share"

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

vest 100% financial

"The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting"

annual meeting of shareholders financial

"vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did SOPH director Didier Hirsch receive on June 18, 2026?

Director Didier Hirsch received 19,724 restricted stock units and options for 28,818 Ordinary Shares, both at $5.46 per share. These grants are part of his equity compensation and give him additional ownership exposure to SOPHiA GENETICS SA.

How many SOPHiA GENETICS (SOPH) shares does Didier Hirsch hold after this Form 4?

After the reported transactions, Didier Hirsch directly holds 240,220 Ordinary Shares of SOPHiA GENETICS SA. This figure reflects the updated share ownership position following the grant of 19,724 restricted stock units disclosed in the Form 4 filing.

What are the terms of Didier Hirsch’s new SOPH share options?

Hirsch received options for 28,818 Ordinary Shares with a $5.46 exercise price, expiring on June 18, 2036. The options vest 100% at the company’s next scheduled annual shareholder meeting, contingent on his continued service through that vesting date.

When do Didier Hirsch’s new SOPHiA GENETICS RSUs and options vest?

Both the 19,724 restricted stock units and the 28,818 share options vest 100% on the date of SOPHiA GENETICS SA’s next scheduled annual meeting of shareholders, provided Hirsch continues to serve the company through that vesting date, according to the Form 4 footnotes.

Are Didier Hirsch’s SOPH equity transactions open-market buys or compensation grants?

The Form 4 classifies both transactions with code “A” as grant or award acquisitions, not open-market purchases. Footnotes specify restricted stock unit and stock option grants, indicating these are compensation-related equity awards rather than discretionary market buys.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/22/2026 - 04:01 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HIRSCH DIDIER

(Last) (First) (Middle)

C/O SOPHIA GENETICS INC.

401 PARK DRIVE, FLOOR 5

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
SOPHiA GENETICS SA [ SOPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/18/2026		A		19,724(1)	A	$5.46	240,220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$5.46	06/18/2026		A		28,818		(2)	06/18/2036	Ordinary Shares	28,818	$5.46	218,569	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") grant. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to Reporting Person's continued service with the Issuer. The RSUs were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders.

2. The share options were granted on June 18, 2026 and vest 100% as of the date of the Issuer's next scheduled annual meeting of shareholders, subject to the Reporting Person's continued service to the Issuer through the relevant vesting date.

Remarks:

	/s/ Elimara Brunetto as Attorney-in-fact for Didier Hirsch	06/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)